Anett Hudák | Neurodegeneration | Women Researcher Award

Published on by Cognitive Scientist Awards

Ms. Anett Hudák | Neurodegeneration | Women Researcher Award

Anett Hudák is a skilled molecular biologist with deep expertise in neurobiology, virology, and molecular pathology. She earned her MSc in Molecular Biology from the University of Debrecen with a specialization in biomedical sciences and pharmacology. Over the years, she has significantly contributed to the understanding of cellular communication, amyloid pathology, and viral entry mechanisms through her work on syndecans. With professional experience spanning academia and industry, Anett currently serves as a molecular biologist at Pharmacoidea Ltd., where she leads impactful research on Alzheimer’s disease, SARS-CoV-2, and neurodegeneration. Her publications in high-impact journals like Scientific Reports and International Journal of Molecular Sciences reflect her strong research acumen. Anett’s extensive training in laboratory techniques, radiation protection, and animal experimentation, along with her dedication and collaborative mindset, make her a valued asset in translational biomedical research. She continues to drive discovery at the intersection of molecular biology and therapeutic innovation.

Profile

🎓 Education

Anett Hudák began her academic journey at Benka Gyula Lutheran Primary School and graduated from Andrássy Gyula Secondary School. She completed her BSc in Biology with a specialization in Laboratory Operations at the University of Debrecen’s Faculty of Science and Technology. She further pursued an MSc in Molecular Biology at the University of Debrecen’s Faculty of Medicine, specializing in Biomedical Sciences and Pharmacology. During her studies, she also received extended-level radiation protection training from the University of Debrecen’s Radiation Protection Service. Anett later earned a Certification in Laboratory Animal Science from the Institutional Animal Welfare Committee at Semmelweis University. Her academic formation has been enriched by intensive hands-on research training in various biomedical techniques including PCR, genotyping, electrophoresis, immunohistochemistry, and animal experimentation. This solid educational background has laid the groundwork for her successful transition into a career in academic and industrial molecular biology research.

🧪 Experience

Anett Hudák has a rich portfolio of research and laboratory experience, beginning with her early work on HPV detection in cervical cancer diagnostics at the Institute of Medical Microbiology, University of Debrecen. She expanded her expertise during her research internship at the Department of Anatomy, Histology and Embryology, where she investigated IL-1RI’s role in inflammatory pain models. From 2012 to 2014, she gained proficiency in cell biology techniques including immunofluorescence and Western blotting. She worked as a laboratory biologist at the Institute of Physiology, Semmelweis University (2015–2016), contributing to studies on lymphangiogenesis in embryonic development. Since 2016, she has been a molecular biologist at Pharmacoidea Ltd., conducting translational research on syndecans in viral transmission, amyloid aggregation, and neurodegenerative diseases. Her contributions to scientific conferences and collaborative publications demonstrate her ability to lead and participate in high-impact research projects that bridge molecular science and therapeutic development.

🏅 Awards and Honors

While formal awards are not extensively listed in Anett Hudák’s CV, her achievements are evident through her selection for prominent speaking roles and poster presentations at respected conferences such as the Pannonia Congress of Pathology (2014), MÉT 2015, and FAMÉ 2016. Her research has consistently been showcased in these forums, highlighting its relevance and impact. Furthermore, Anett’s work has resulted in numerous peer-reviewed publications in top-tier journals like Scientific Reports and International Journal of Molecular Sciences, indicating recognition by the scientific community. Her collaborative publications with international experts, such as Martin Hofmann-Apitius and Mimoun Azzouz, underscore her respected standing in biomedical research. Anett’s ability to lead first-author publications and contribute significantly to multi-author research reflects a level of distinction that is often synonymous with academic honors. Her rising trajectory in neurodegenerative and virology research suggests she is well-positioned for future scientific accolades and leadership roles.

🔬 Research Focus

Anett Hudák’s research centers on the role of syndecans in cellular communication, neurodegenerative disease pathology, and viral entry mechanisms. Her work has significantly contributed to understanding how these membrane proteins facilitate the internalization and aggregation of amyloid-β, α-synuclein, and tau—key proteins involved in Alzheimer’s and Parkinson’s diseases. She also explores how syndecans enable SARS-CoV-2 entry, including variants like Delta and Omicron, offering insights into COVID-19 pathogenesis and therapeutic intervention. Recent studies delve into the interaction between apolipoproteins and syndecans and how these pathways impact cellular events relevant to amyloid disorders. Her use of tissue decolorization, single-cell resolution imaging, and endocytosis analysis has positioned her research at the forefront of molecular neuroscience and virology. Anett’s interdisciplinary approach, spanning molecular biology, cell signaling, and pathology, not only addresses fundamental mechanisms but also aims to inform novel therapeutic strategies for infectious and neurodegenerative diseases.

✅ Conclusion

Anett Hudák is a dedicated and impactful molecular biologist whose research on syndecans, neurodegeneration, and viral entry has advanced both basic science and translational applications in biomedicine.

Publications

Jesus Avila | Tauopathies | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Jesus Avila | Tauopathies | Best Researcher Award

Dr. Jesus Avila is a distinguished cognitive scientist and Professor ad honorem at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), Spain. He obtained his degree in Chemistry and PhD in Molecular Biology from Universidad Complutense Madrid, focusing on RNA polymerase in B. subtilis. His postdoctoral research at NIH, USA, centered on the SV40 virus. Throughout his prolific career, Dr. Avila has made groundbreaking contributions to understanding the neuronal cytoskeleton, particularly tau protein, its role in Alzheimer’s disease, and tauopathies. With over 694 published journal articles, 33 books, 4 patents, and collaborations across the USA, France, UK, Germany, and Spain, his work is internationally recognized. He serves on editorial boards of prestigious journals including EMBO J, FEBS Letters, Neuroscience, and Journal of Alzheimer’s Disease (Deputy Editor). Dr. Avila is a member of EMBO, Academia Europaea, AAAS, and Royal Academies of Sciences and Medicine of Spain.

Professional Profile

Education

Dr. Jesus Avila pursued his higher education at Universidad Complutense Madrid (UCM), earning a degree in Chemistry. He further specialized by completing a PhD in Molecular Biology at UCM, where his research focused on the B. subtilis RNA polymerase system. This solid foundation in molecular biology provided him with the expertise to investigate complex neurobiological mechanisms. He then advanced his academic career with postdoctoral training at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, where he studied the SV40 virus—a crucial step that introduced him to advanced molecular virology and neurobiology techniques. This diverse academic background enabled him to establish a globally recognized research portfolio in neurodegeneration, particularly tau protein’s role in neuronal function and dysfunction.

Experience

Dr. Avila has an illustrious career spanning several decades at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), where he has led pioneering research into the neuronal cytoskeleton, tau protein dysfunction, and neurodegenerative diseases. His early research at NIH on SV40 virus provided him with robust molecular expertise, which he translated into comprehensive studies on tauopathies and Alzheimer’s disease upon returning to Spain. Dr. Avila has successfully led over 30 major research projects, consulted on 8 industry collaborations, and published 694 peer-reviewed articles. His work includes the authorship of 33 books and the filing of 4 patents. Through sustained collaborations with global leaders in neuroscience from the USA, France, UK, Germany, and Spain, he has significantly advanced the understanding of aging and cognitive decline. His academic leadership and editorial roles underscore his vast experience in guiding both research and scientific discourse.

Research Interests

Dr. Avila’s research primarily investigates the neuronal cytoskeleton, with a central focus on tau protein and its role in neurodegeneration. Beginning with tau’s structural function in neurons, his work has expanded to explore how tau dysfunction contributes to Alzheimer’s disease and other tauopathies. Utilizing molecular and cellular approaches, including advanced mouse models, he has dissected the pathological mechanisms linking tau pathology to cognitive decline. Recognizing aging as the principal risk factor for Alzheimer’s disease, his current investigations target neuronal rejuvenation strategies to mitigate age-associated neurodegeneration. His integrative approach combines molecular biology, neurogenetics, and translational models, contributing significantly to the understanding of disease progression and potential therapeutic interventions. Through over 694 publications, 33 books, multiple patents, and international collaborations, Dr. Avila has substantially advanced the field of cognitive neuroscience, particularly in understanding and combating tau-mediated cognitive disorders.

Awards

Dr. Avila’s exemplary contributions have earned him numerous prestigious honors. He is an elected member of EMBO (European Molecular Biology Organization), Academia Europaea, AAAS (American Association for the Advancement of Science), and both the Royal Academies of Sciences and Medicine of Spain—testament to his global recognition and scientific excellence. His editorial appointments with highly respected journals such as EMBO J, FEBS Letters, Neuroscience, and his role as Deputy Editor of the Journal of Alzheimer’s Disease further validate his authority in cognitive and neurodegenerative research. His citation index surpasses 100 on Scopus, reflecting the significant influence of his work. His extensive collaborations with leading international research teams highlight his status as a respected leader in the global scientific community. The combination of his research excellence, mentorship, and leadership has positioned him as one of the foremost experts in cognitive science and neurobiology.

Conclusion

Dr. Jesus Avila’s distinguished career combines pioneering research on tau protein and Alzheimer’s disease, extensive international collaborations, over 694 publications, leadership roles in major journals, multiple prestigious memberships, and an unwavering focus on neuronal rejuvenation strategies, positioning him as a world-leading cognitive scientist whose work continues to advance global understanding of neurodegeneration.

 Publications

  • Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer’s disease

    Experimental Neurology
    2025 | Journal article
    DOI: 10.1016/j.expneurol.2024.115049

    EID:

    2-s2.0-85208758184

    Part ofISSN: 10902430 00144886
    CONTRIBUTORS: Merino-Serrais, P.; Soria, J.M.; Arrabal, C.A.; Ortigado-López, A.; Esparza, M.Á.G.; Muñoz, A.; Hernández, F.; Ávila, J.; DeFelipe, J.; León-Espinosa, G.

  • Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System

    International Journal of Molecular Sciences
    2025-05-04 | Journal article
    DOI: 10.3390/ijms26094368
    CONTRIBUTORS: Laura Vallés-Saiz; Aaron Abdelkader-Guillén; Jesús Ávila; Félix Hernández

  • Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments

    Biochemistry
    2025-04-15 | Journal article
    DOI: 10.1021/acs.biochem.4c00809
    CONTRIBUTORS: Indalo Domene-Serrano; Raquel Cuadros; Vega García-Escudero; Francisco Vallejo-Bedia; Ismael Santa-María; Laura Vallés-Saiz; Félix Hernandez; Jesús Avila

  • Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery

    ACS Omega
    2025-04-08 | Journal article
    DOI: 10.1021/acsomega.4c10849
    CONTRIBUTORS: Alejandro Anton-Fernandez; Indalo Domene-Serrano; Raquel Cuadros; Rocio Peinado-Cahuchola; Margarita Sanchez-Pece; Felix Hernandez; Jesus Avila

  • Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer\’s disease

    Progress In Neurobiology
    2025-04-01 | Journal article | Author
    DOI: 10.1016/j.pneurobio.2025.102743

    SOURCE-WORK-ID:

    CSIC-GB950859

    EID:

    2-s2.0-85219079150

    Part ofISSN: 0301-0082
    CONTRIBUTORS: Alejandro Anton-Fernandez; Ruiz de Alegría, Álvaro; Mariscal-Casero, Ana; Roldán-Lázaro, Marta; Peinado-Cauchola, Rocío; Jesus Avila; Felix Hernandez

  • Hippocampal rejuvenation by a single intracerebral injection of one‐carbon metabolites in C57BL6 old wild‐type mice

    Aging Cell
    2025-01 | Journal article
    DOI: 10.1111/acel.14365
    CONTRIBUTORS: Alejandro Antón‐Fernández; Rocío Peinado Cauchola; Félix Hernández; Jesús Ávila

  • Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3

    eBioMedicine
    2024 | Journal article
    DOI: 10.1016/j.ebiom.2023.104953

    EID:

    2-s2.0-85181837483

    Part ofISSN: 23523964
    CONTRIBUTORS: Ruiz-Gabarre, D.; Vallés-Saiz, L.; Carnero-Espejo, A.; Ferrer, I.; Hernández, F.; Garcia-Escudero, R.; Ávila, J.; García-Escudero, V.

  • Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer´s disease in Prnp mutant mice and in the P301S transgenic tauopathy mice model

    bioRxiv
    2024 | Other
    DOI: 10.1101/2024.01.20.576414

    EID:

    2-s2.0-85184321414

    Part of ISSN: 26928205
    CONTRIBUTORS: Sala-Jarque, J.; Gil, V.; Andrés-Benito, P.; Lidón, L.; Yanac-Huertas, R.E.; López-León, C.F.; Hernández, F.; Ávila, J.; Lanciego, J.L.; Soriano, J. et al.

Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu is a professor at the Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan, and an adjunct professor in several prestigious institutions. With a PhD in Life Science from National Tsing-Hua University, his academic and industrial experiences span cancer genetics, precision medicine, and biopharmaceuticals. He has held positions at Johns Hopkins Medical Institutions and Development Center for Biotechnology. His research explores molecular mechanisms underlying diseases such as cancer and endometriosis, employing genome-wide technologies to identify biomarkers and drug targets. He actively contributes to biomedical innovation, translational medicine, and mentorship. Dr. Sheu has received numerous national and international awards, including the Wu-Da-You Memorial Award and Sigma Xi membership. He is also an ambassador for the European Association for Cancer Research. As a prolific researcher and reviewer, he plays key roles in research councils and institutional review boards, helping shape scientific policy and translational biomedical advancements in Taiwan and beyond.

Profile

Education 🎓

Dr. Sheu earned his Ph.D. in Life Science from National Tsing-Hua University, Taiwan, in 2002, where he focused on advanced molecular biology, gene expression regulation, and biomedical research. His doctoral training provided a strong foundation in cancer genetics and systems biology. Earlier, he completed his B.S. in Biology (now Life Science) from Fu-Jen University in 1994, building core competencies in biological sciences and cellular mechanisms. These educational milestones equipped him with theoretical knowledge and technical skills in genomics, proteomics, and cellular signaling, which are now reflected in his research on chromatin remodeling, cancer biomarkers, and therapeutic targets. Through rigorous academic mentorship, Dr. Sheu gained early exposure to multidisciplinary research and critical analysis, fostering his interest in precision medicine. His academic background laid the groundwork for his contributions to biomedical research, drug development, and translational science. These formative years in Taiwan’s top universities underpin his long-standing excellence in scientific discovery and innovation.

Experience 👨‍🏫

Dr. Sheu’s professional experience includes faculty roles and research leadership across academia and industry. He has served as a Professor at National Sun Yat-sen University since 2014 and previously held faculty roles at China Medical University. Internationally, he was a Research Fellow at Johns Hopkins Medical Institutions (2004–2006). Between 2003–2004, he worked in various leadership positions at the Development Center for Biotechnology, including Director of Protein Drugs Division and Project Leader. His postdoctoral and early research roles included work with Dr. Tse-Wen Chang and Dr. Carmay Lim at Academia Sinica. His academic leadership includes roles such as Associate VP of R&D, Chair of the Institute of Biomedical Sciences, and Director of Research Resources at NSYSU. He has reviewed research proposals for numerous hospitals and institutions, served on IRBs, and guided government research policy. His diverse experience bridges basic science, translational research, and biomedical entrepreneurship with national and global impact.

Awards & Recognitions 🏅

Dr. Sheu has received over 30 prestigious awards. In 2023 alone, he earned the Tien-Te Lee Award, NSYSU Outstanding Faculty Award, and top honors at the 37th Joint Biomedical Conference. He previously received the Prof. Chii-Ruey Tzeng Award, Sigma Xi membership (2021), and EACR Ambassador role (2020). His innovation was recognized by Future Tech Award and the 2020 Smart Life Innovation Competition. His studies were featured as Taiwan Research Highlights and F1000Prime recommendations. He was the 2014 recipient of the Wu-Da-You Memorial Award and the IBC Outstanding Scientific Achievement Award. He received the Medical Young Investigator Award in 2009 and the Best Basic Science Award at Johns Hopkins in 2005. As a government-financed scholar to the U.S., his academic excellence has been internationally recognized. He consistently ranks among Taiwan’s top biomedical researchers, illustrating his impact through award-winning research in endometriosis, cancer stemness, diagnostics, and therapeutic innovation.

Research Interests 🔬

Dr. Sheu’s research focuses on cancer genetics and genomics, endometriosis, precision medicine, chromatin remodeling, cytoskeletal dynamics, cell adhesion and invasion, and mechanotransduction. His lab investigates how abnormalities in gene expression and chromatin structure drive disease progression, especially in gynecologic cancers and endometriosis. By applying genome-wide analysis and bioinformatics, his team identifies disease-driving genes and develops novel diagnostic tools and therapeutic strategies. A key interest is the tumor microenvironment and how cytoskeletal networks and nuclear architecture influence cancer stemness and metastasis. His group explores traditional Chinese medicine compounds and stem cell therapies, advancing integrative approaches to medicine. Antibody and vaccine engineering are also integral to his translational pipeline. Funded by NSTC Taiwan and other institutions, his projects target non-invasive diagnostics and biomarker-based interventions. His long-term vision involves bridging molecular biology, clinical application, and therapeutic innovation to impact patient care and global health through interdisciplinary and precision-driven biomedical science.

Publications

Fan Zhang | Proteomics | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Fan Zhang | Proteomics | Best Researcher Award

Fan Zhang, born on September 23, 1991, is a postdoctoral researcher specializing in cancer proteogenomics 🔬. He is currently with the Department of Pathology at Duke University 🏛️. His research leverages mass spectrometry and bioinformatics 🖥️ to investigate metabolic pathways in therapy-resistant prostate cancer and other malignancies. He has received the FY23 Prostate Cancer Research Program Early Investigator Research Award 🏆 for his work on glutamine metabolism in advanced prostate cancer. His contributions to proteogenomics have resulted in multiple high-impact publications 📄 in Nature Communications, Cell Research, and Molecular & Cellular Proteomics. Proficient in LC-MS/MS, bioinformatics analysis, and experimental techniques, his research bridges the gap between basic cancer biology and clinical applications 🏥, paving the way for novel therapeutic strategies in oncology.

Profile

Education 🎓

Fan Zhang holds a Ph.D. in Biochemistry and Molecular Biology from Fudan University (2015-2020), where he focused on proteogenomic research. He further pursued postdoctoral training in Clinical Medicine at Fudan University (2020-2022) before joining Duke University as a postdoctoral researcher in the Department of Pathology in 2023. His academic journey began with a B.S. in Applied Biological Science from Anhui Agricultural University (2011-2015). Throughout his education, he gained expertise in genomics, transcriptomics, and proteomics, developing a strong foundation in bioinformatics and experimental methodologies. His interdisciplinary training has equipped him with skills in mass spectrometry-based proteomics, omics data analysis, and cancer metabolism research. His current research at Duke University focuses on metabolic vulnerabilities in prostate cancer, aiming to develop targeted therapies. His diverse academic background enables him to integrate various scientific disciplines, contributing significantly to cancer research and precision medicine.

Experience 👨‍🏫

Fan Zhang has extensive research experience in cancer proteogenomics. Currently a postdoctoral researcher at Duke University (2023-present), he investigates metabolic vulnerabilities in prostate cancer using advanced mass spectrometry and omics analysis. Previously, he was a postdoc in Clinical Medicine at Fudan University (2020-2022), where he contributed to proteogenomic studies on various cancers, including pituitary neuroendocrine tumors and diffuse large B-cell lymphoma. His Ph.D. at Fudan University (2015-2020) focused on proteogenomic characterizations of cancer, leading to high-impact publications. He is proficient in LC-MS/MS, bioinformatics, and experimental methodologies such as Western blotting, immunofluorescence, and cell culture. His research integrates mass spectrometry with genomics and transcriptomics to uncover novel therapeutic targets. With expertise in multi-omics data analysis, he has significantly contributed to the field of cancer biology. His work is supported by prestigious grants, highlighting his role as a leading researcher in proteogenomics and precision oncology.

Research Interests 🔬

Fan Zhang’s research focuses on proteogenomics and cancer metabolism, particularly in therapy-resistant malignancies like prostate cancer, pituitary neuroendocrine tumors, and diffuse large B-cell lymphoma. He specializes in mass spectrometry-based proteomics (DDA, DIA) and integrates multi-omics approaches, including genomics, transcriptomics, and metabolomics, to uncover novel cancer vulnerabilities. His current work at Duke University investigates glutamine metabolism in castration-resistant prostate cancer, aiming to develop targeted therapies. His expertise extends to bioinformatics analysis, large-cohort omics data interpretation, and advanced LC-MS/MS techniques for various biological samples. His research has led to multiple high-impact publications, highlighting his ability to translate complex molecular data into potential clinical applications. By combining experimental and computational approaches, he aims to identify biomarkers and therapeutic targets that can improve cancer treatment. His contributions to proteogenomics play a crucial role in advancing precision oncology and understanding the metabolic reprogramming of aggressive cancers.

 

Awards & Recognitions 🏅

Fan Zhang has received multiple awards and recognitions for his contributions to cancer proteogenomics. He was awarded the Fiscal Year 2023 (FY23) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (2023-2025) for his project on targeting glutamine metabolism in advanced prostate cancer (Award Number HT9425-24-1-0237). His research has been recognized through multiple first-author and co-first-author publications in high-impact journals such as Nature Communications, Molecular & Cellular Proteomics, Cell Research, and The Prostate. His work has also been featured as a cover article in Cell Research (2022). His expertise in mass spectrometry, proteogenomics, and bioinformatics has positioned him as a leading young investigator in the field. In addition to research grants, he has received accolades for his innovative contributions to metabolic studies in oncology. His commitment to advancing cancer research has been instrumental in developing novel therapeutic strategies for therapy-resistant malignancies.

Publications 📚

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication